Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 11 publications
Population pharmacokinetic rationale for intravenous contezolid acefosamil followed by oral contezolid dosage regimens.
Journal: Antimicrobial agents and chemotherapy
Published: February 28, 2024
Contezolid can replace linezolid in a novel combination with bedaquiline and pretomanid in a murine model of tuberculosis.
Journal: Antimicrobial agents and chemotherapy
Published: November 15, 2023
In Vitro and In Vivo Activities of Contezolid (MRX-I) against Mycobacterium tuberculosis.
Journal: Antimicrobial agents and chemotherapy
Published: March 15, 2018
Single- and Multiple-Dose Study To Determine the Safety, Tolerability, Pharmacokinetics, and Food Effect of Oral MRX-I versus Linezolid in Healthy Adult Subjects.
Journal: Antimicrobial agents and chemotherapy
Published: October 10, 2016
Safety, tolerability and pharmacokinetics of multiple oral doses of AFN-1252 administered as immediate release (IR) tablets in healthy subjects.
Journal: Journal of chemotherapy (Florence, Italy)
Published: October 03, 2015
Efficacy and Safety of AFN-1252, the First Staphylococcus-Specific Antibacterial Agent, in the Treatment of Acute Bacterial Skin and Skin Structure Infections, Including Those in Patients with Significant Comorbidities.
Journal: Antimicrobial agents and chemotherapy
Published: July 22, 2015
AFN-1252 in vitro absorption studies and pharmacokinetics following microdosing in healthy subjects.
AFN-1252 in vitro absorption studies and pharmacokinetics following microdosing in healthy subjects.
Journal: European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences
Published: April 26, 2013
In vitro activity (MICs and rate of kill) of AFN-1252, a novel FabI inhibitor, in the presence of serum and in combination with other antibiotics.
Journal: Journal of chemotherapy (Florence, Italy)
Published: February 26, 2013
Pharmacokinetics, pharmacodynamics and efficacy of novel FabI inhibitor AFN-1252 against MSSA and MRSA in the murine thigh infection model.
Journal: Journal of chemotherapy (Florence, Italy)
Published: February 26, 2013
Mode of action, in vitro activity, and in vivo efficacy of AFN-1252, a selective antistaphylococcal FabI inhibitor.
Journal: Antimicrobial agents and chemotherapy
Published: September 06, 2012
Showing 1-11 of 11
Last Updated: 09/26/2026